Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-31
2006-10-31
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S429000
Reexamination Certificate
active
07129262
ABSTRACT:
The present invention provides novel indole derivatives useful to inhibit cancer or sensitize cancer cells to chemotherapeutic agents, radiation or other anti-cancer treatments.
REFERENCES:
patent: 3053255 (1962-09-01), Meyer
patent: 3710795 (1973-01-01), Higuchi et al.
patent: 3843480 (1974-10-01), Dreher
patent: 3843681 (1974-10-01), Demerson et al.
patent: 3939178 (1976-02-01), Demerson et al.
patent: 3948254 (1976-04-01), Zaffaroni
patent: 3948262 (1976-04-01), Zaffaroni
patent: 3974179 (1976-08-01), Demerson et al.
patent: 3993073 (1976-11-01), Zaffaroni
patent: 4041169 (1977-08-01), Demerson et al.
patent: 4179503 (1979-12-01), Asselin et al.
patent: 4310509 (1982-01-01), Berglund et al.
patent: 4337760 (1982-07-01), Rubin
patent: 4460562 (1984-07-01), Keith et al.
patent: 4466953 (1984-08-01), Keith et al.
patent: 4482534 (1984-11-01), Blank
patent: 4485097 (1984-11-01), Bell
patent: 4505891 (1985-03-01), Ito
patent: 4533540 (1985-08-01), Blank
patent: 4542012 (1985-09-01), Dell
patent: 4542013 (1985-09-01), Keith et al.
patent: 4560555 (1985-12-01), Snider
patent: 4585877 (1986-04-01), Demerson et al.
patent: 4597961 (1986-07-01), Etscorn
patent: 4608249 (1986-08-01), Otsuka
patent: 4686213 (1987-08-01), Ferdinandi et al.
patent: 4748252 (1988-05-01), Ferdinandi et al.
patent: 4806356 (1989-02-01), Shaw
patent: 4940587 (1990-07-01), Jenkins et al.
patent: 5561151 (1996-10-01), Young et al.
patent: 5599946 (1997-02-01), Vincenzo et al.
patent: 5776967 (1998-07-01), Kreft et al.
patent: 5780435 (1998-07-01), Garnick et al.
patent: 5811558 (1998-09-01), Adger et al.
patent: 5824699 (1998-10-01), Kreft et al.
patent: 5939455 (1999-08-01), Rephaeli
patent: 5955504 (1999-09-01), Wechter et al.
patent: 5968974 (1999-10-01), Kargman et al.
patent: 5981592 (1999-11-01), Wechter et al.
patent: 6066741 (2000-05-01), Vigano' et al.
patent: 6110955 (2000-08-01), Nudelman et al.
patent: 6160018 (2000-12-01), Wechter et al.
patent: 6300313 (2001-10-01), Engel et al.
patent: 6545034 (2003-04-01), Carson et al.
patent: 6552055 (2003-04-01), Spiegelman et al.
patent: 2002/0042375 (2002-04-01), Heimbrook et al.
patent: 2003/0004142 (2003-01-01), Prior et al.
patent: 2003/0004143 (2003-01-01), Prior et al.
patent: 1299577 (1992-04-01), None
patent: 2226340 (1973-03-01), None
patent: 0289262 (1986-11-01), None
patent: 1436893 (1976-05-01), None
patent: WO-96/28148 (1996-09-01), None
patent: WO-97/48391 (1997-12-01), None
patent: WO-98/09603 (1998-03-01), None
patent: WO-98/18490 (1998-05-01), None
patent: WO-98/40078 (1998-09-01), None
patent: WO-00/02555 (2000-01-01), None
patent: WO-01/06990 (2001-02-01), None
patent: WO-02/02125 (2002-01-01), None
patent: WO-02/12188 (2002-02-01), None
The Merck Index, Thirteenth Edition, Budavari, S., et al., (eds.), Merck & Co., Inc., Rahway, N.J., “Etodolac, Entry No. 3905 ”,(1990),p. 685.
In: Remington's Pharmaceutical Sciences, Eighteenth Edition, Gennaro, A.R., (ed.), Mack Publishing Company, Easton, PA,(1990),pp. 1115-1122.
Drug Facts and Comparisons, 1995 Edition, Wolters Kluwer Co.,(1995),2775-2789.
“1991 New Drugs”,US Pharmacist, 61, (Sep. 1991),35-40, 42, 44,46, 48-50, 52, 57-58, 60, 62, 64 (Pages not cited are advertisements).
Abramson, S. B., et al., “The Mechanisms of Action of Nonsteroidal Antiinflammatory Drugs”,Arthritis&Rheumatism, 32(1), (Jan. 1989),1-9.
Alexanian, R. , et al., “The Treatment of Multiple Myeloma”,The New England Journal of Medicine, 330 (7), (Feb. 17, 1994),484-489.
Barlogie, B , et al., “Prognostic Factors with High-Dose Melphalan for Refractory Multiple Myeloma.”,Blood, 72(6), (Dec. 1988),2015-2019.
Bataille, R , et al., “Multiple Myeloma”,New England Journal of Medicine, 336, (1997), 1657-1664.
Becker-Scharfenkamp, U., et al., “Evaluation of the Stereoselective Metabolism of the Chiral Analgesic Drug Etodolac by High-Performance Liquid Chromatography”,Journal of Chromatography, 621(2), (Nov. 24, 1993),pp. 199-207.
Bellosillo, B., et al., “Aspirin and Salicylate Induce Apoptosis and Activation of Caspases in B-Cell Chronic Lymphocytic Leukemia Cells”,Blood, 92 (4), (Aug. 15, 1998), 1406-1414.
Berendes, U. , et al., “Simultaneous Determination of the Phase II Metabolites of the Non Steroidal Anti-Inflammatory Drug Etodolac in Human Urine”,Enantiomer, 1, Abstract Only, Chemical Abstracts, Abstract No. 126:207064q, (1996), 415-422.
Brenna, E., et al., “New Enzymatic and Chemical Approaches to Enantiopure Etodolac”,Tetrahedron, 53, (1997),17769-17780, submitted twice.
Brocks, D. R., et al., “Etodolac Clinical Pharmacokinetics”,Clinical Pharmacokinetics, 26(4), (1994),pp. 259-274.
Carson, D. A., et al., “Oral Antilymphocyte Activity and Induction of Apoptosis by 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine”,Proceedings of the National Academy of Sciences USA, 89(7), (Apr. 1, 1992),2970-2974.
Chinetti, G. , et al., “Activation of Proliferator-activated Receptors α and γ Induces Apoptosis of Human Monocyte-derived Macrophages”,Journal of Biological Chemistry, 273 (40), (Oct. 2, 1998),25573-25580.
Cunningham, D , et al., “High-dose Melphalan for Multiple Myeloma: Long-term Follow-up Data”,Journal of Clinical Oncology, 12, (1994),764-768.
Demerson, C. A., et al., “Etodolic Acid and Related Compounds. Chemistry and Antiinflammatory Actions of Some Potent Di- and Trisubstituted 1,3,4,9-Tetrahydropyrano[3,4-b]indole-1-acetic Acids”,Journal of Medicinal Chemistry, 19 (3), (1976),pp. 391-395.
Demerson, C. A., et al., “Resolution of Etodolac and Antiinflammatory and Prostaglandin Synthetase Inhibiting Properties of the Enantiomers”,J. Med. Chem., 26 (12), (Dec. 1983),pp. 1778-1780.
Drachenberg, D. E., “Treatment of Prostate Cancer: Watchful Waiting, Radical Prostatectomy, and Cryoablation”,Seminars in Surgical Oncology, 18 (1), (Jan./Feb. 2000),pp. 37-44.
Duffy, C. P., et al., “Enhancement of Chemotherapeutic Drug Toxicity to Human Tumour CellsIn Vitroby a Subset of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)”,European Journal of Cancer, 34 (8), (Jul. 1998),pp. 1250-1259.
Hahnfeld, L. E., et al., “Prostate Cancer”,The Medical Clinics of North America—The Aging Male Patient, 83 (5),pp. 1231-1245.
Harousseau, J. L., et al., “Double-Intensive Therapy in High-Risk Multiple Myeloma”,Blood, 79 (11), (Jun. 1, 1992),pp. 2827-2833.
Heath, Clark W., “Nonsteroidal Antiinflammatory Drugs and Human Cancer”,American Cancer Society, vol. 74, No. 10, (Nov. 15, 1994),2885-2886.
Krajewski, S. , et al., “Detection of Multiple Antigens on Western Blots”,Analytical Biochemistry, 236 (2), Article No. 0160,(May 1996),pp. 221-228.
Landis, S. H., et al., “Cancer Statistics, 1998”,CA Cancer J. Clin., 48 (1), 1998,pp. 6-29.
Lee, D. H., “Proteasome Inhibitors: Valuable New Tools For Cell Biologists”,Trends in Cell Biology, 8, (Oct. 1998),pp. 397-403.
Lehmann, J. M., et al., “Peroxisome Proliferator-activated Receptors α and γ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs”,Journal of Biological Chemistry, 272 (6), (Feb. 7, 1997),3406-3410.
Leman, Eddy S., et al., “Characterization of the Nuclear Matrix Proteins in a Transgenic Mouse Model for Prostate Cancer”,Journal of Cellular Biochemistry, 86, (2002),203-212.
Leoni, L. M., et al., “Induction of an Apoptotic Program in Cell-Free Extracts by 2-Chloro-2′-deoxyadenosine 5′-triphosphate and Cytochrome C”,PNAS, USA, 95 (16), (Aug. 4, 1998),pp. 9567-9571.
Lochmüller, C. H., et al., “Chromatographic Resolution of Enantiomers—Selective Review”,Journal of Chromatography, 113 (3), (Oct. 22, 1975),283-302.
Martel, R. R., et al., “Anti-inflammatory and Analgesic Properties of Etodolic Acid in Rats”,Canadia
Carson Dennis A.
Cottam Howard B.
Leoni Lorenzo M.
Barker Michael P.
Saeed Kamal A.
Schwegman Lundberg Woessner & Kluth P.A.
The Regents of The University of California
LandOfFree
Indole compounds useful for the treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indole compounds useful for the treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indole compounds useful for the treatment of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3718977